Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer

Inclusion Criteria:

* Female patient aged 18 years or over.
* Patient understands French.
* Patient covered by the French national health insurance system.
* Any female patient scheduled for breast surgery with mastectomy and axillary node dissection indicated at the pre-surgical stage.

Exclusion Criteria:

* Patient under the age of 18 years.
* Patient who does not understand French.
* Patient not covered by the French national health insurance system.
* Patient exhibiting one or more contraindications to anesthesia and surgery.
* Patient with a contra-indication to pasireotide
* Refusal by the patient
* Scheduled sentinel node procedure
* Abnormal coagulation or curative anticoagulant treatment
* Women of child-bearing potential without effective contraception,
* Pregnant or breast-feeding women
* Poorly controlled diabetes (HbA1c \> 8%)
* History of radiotherapy
* Recurrent breast cancer
* Patient with a congestive cardiac insufficiency (NYHA category III or IV), an instable angina pectoris, sustained ventricular tachycardia or ventricular fibrillation episodes or history of myocardial infarction during the last 6 months.
* Patient presenting an extension of QT interval (QT corrected according to the Fridericia formula (QTcF)) at the screening or baseline (predose) \> 450msec
* History of syncope or family history of sudden death or significant cardiac arrhythmia
* Risk factors for torsades de pointes: hypokaliaemia, hypomagnesaemia, known structural or ischaemic cardiac disease, bradycardia (HR\<55/min) or high grade AV block
* Concomitant disease that could prolong QT or increase exposure to the study medication including dehydration, renal or hepatic impairment
* Concomitant medication known to increase the QT interval
* Patient with an hepatic pathology such as cirrhosis, chronic hepatitis active or persistent, or an elevation of ALAT rate, ASAT rate twice higher than the normal superior limit (NSL)
* Patient having leucocytes \< 3x109/L, Hb \< 90% LIN, platelets \< 100x109/L
* Patient having a pathology or medical history susceptible to interfere with the realization of the study or results evaluation according to the judgment of the investigator or the study monitor
* Patient participating to another clinical trial with another molecule in study during the month before the first dose
* Known oversensitivity to somatostatine analogs or another component of prolonged release pasireotide or prolonged release octreotide formulations.